Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In a first, scientists used computer simulations to identify the vaccines most likely to be effective against respiratory syncytial virus (RSV), the most common cause of infant severe pneumonia worldwide.

Lisa White in front of a computer describing math models

30 November 2016 (Bangkok) – In a first, scientists used computer simulations to identify the vaccines most likely to be effective against respiratory syncytial virus (RSV), the most common cause of infant severe pneumonia worldwide.

Although there is no vaccine yet available for RSV, a viral infection that annually kills up to 200,000 children under five globally, a study published online today in Vaccine suggests that the most effective vaccine would be one that stops RSV from spreading in the general population rather than one that completely prevented disease in RSV-infected individuals.

“This approach radically alters the way we decide which promising vaccine to develop. Choosing which new vaccines to develop from many possible candidates is an expensive process. As using mathematical modelling helps do that more efficiently, we expect that the pharmaceutical industry will use this approach more and more in the future,” says study leader Prof. Lisa White, of the University of Oxford, and Head of Mathematical and Economic MODelling (MAEMOD) at the Mahidol Oxford Tropical Medicine Research Unit (MORU) in Bangkok, Thailand.

“We used mathematical modelling simulations to find the best choices among candidate anti-RSV vaccines, and were surprised to find that the most effective vaccines would not provide solid immunity to reinfection but would reduce the infectiousness of infected individuals, thereby protecting the community at large by reducing the amount of virus in circulation,” explained study co-author Dr Wirichada Pan-Ngum, Deputy Head of Mathematical Modelling at MORU.

Funded by the Wellcome Trust, the study, a collaboration between researchers linked to the universities of Oxford, Warwick and Manchester in the UK and Mahidol University, Thailand, in partnership with global vaccine developer GSK-Biologicals, Belgium, examined which properties RSV vaccines under development would need to have to be most effective in preventing RSV in young children.

The researchers were linked by a new network of mathematical modelers based in the Tropics (TDMODNET). The network is a highly innovative environment which nurtures talented mathematicians from Asia and Africa. “We have proven that true world-class innovation can come from a South-South collaboration of scientists,” said study contributor Dr Tim Kinyanjui, University of Manchester (UK).

Unlike vaccines that currently control common childhood diseases, new vaccines must target diseases with complex and poorly understood immunity. These diseases nevertheless cause a huge amount of suffering and death.

“RSV is the most important cause of infant severe lower respiratory tract disease worldwide, estimated to be responsible for 3 million hospital admissions annually. Occurring in seasonal outbreaks, RSV causes an inflammatory immune response and that constricts airflow, with many children developing pneumonia or bronchiolitis,” says study co-author and major RSV researcher Prof. James Nokes, of the University of Warwick and the Kenya Medical Research Institute (KEMRI)/Wellcome Trust in Kilifi, Kenya.

“New vaccines demand new development pathways and this research is the first to use computer simulation to support the process,” said Prof. Nokes.

Reference

Predicting the relative impacts of maternal and neonatal respiratory syncytial virus (RSV) vaccine target product profiles: A consensus modelling approach. Pan-Ngum W, Kinyanjui T, Kiti M, Taylor S, Toussaint JF, Saralamba S, Van Effelterre T, Nokes DJ and White LJ. DOI: 10.1016/j.vaccine.2016.10.073, Online publication: 14 Dec 2016, in Vaccine, Volume 35, issue 2 (2016)l

Similar stories

Congratulations new Associate Professors

Following the meeting of the Medical Sciences Divisional Committee to consider applications for the conferral of the title of Associate Professor, we are pleased to announce that Rashan Haniffa, Dorcas Kamuya, Isabella Oyier, Le Van Tan and Timothy Walker have been awarded the title Associate Professor

COPCOV now world’s largest COVID-19 pre-exposure prophylaxis trial

A 6-week recruitment burst at Aga Khan University in Pakistan led the way as COPCOV enrolment broke 1600 participants. Led by MORU, COPCOV is the world’s largest trial trying to determine if hydroxychloroquine and chloroquine prevent COVID-19.

How did people in Europe and SE Asia experience the first COVID-19 wave?

An international team, led by Phaik Yeong Cheah, conducted an anonymous online survey from May-June 2020, asking 5,058 people in Thailand, Malaysia, United Kingdom, Italy and Slovenia to share their experiences. Anne Osterrieder and colleagues report the unequal impacts of public health measures, and the prevalence of ‘fake news’.

Recruitment surges in COPCOV COVID-19 prevention study

As high COVID-19 daily cases and highly transmissible variants risk overwhelming countries’ healthcare systems, COPCOV, the world’s last-standing large prophylaxis RCT, faces tight timelines to determine whether chloroquine/ hydroxychloroquine prevents COVID-19

Simple blood tests may help improve malaria diagnosis in clinical studies

About one-third of children diagnosed with severe malaria may instead have an alternative cause of illness, but simple blood tests could help researchers distinguish between the two and speed up research on new treatments.

OUCRU scientists identify combination of biological markers associated with severe dengue

Nguyen Lam Vuong, Sophie Yacoub & colleagues have identified a combination of biological markers in patients with dengue that could predict whether they go on to develop moderate to severe disease. Biomarkers are used to identify the state or risk of a disease in patients; these findings could aid the development of biomarker panels for clinical use and help improve triage and risk prediction in patients with dengue.